![Chris Hollowood](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Chris Hollowood
Presidente en
FREELINE THERAPEUTICS HOLDINGS PLC
.
Perfil
Christopher John Hollowood is the founder of Spur Therapeutics Ltd. since 2015, holding the title of Chairman.
Current jobs include Chief Executive Officer at Syncona Partners LLP since 2023, Chairman at Freeline Therapeutics Holdings Ltd., Chairman at Forcefield Therapeutics Ltd. since 2020, Director at Beacon Therapeutics (USA), Inc., and Director at Syncona Ip Holdco Ltd. Former jobs include Chairman at Nightstar Therapeutics Ltd. from 2013 to 2019, Chairman at Gyroscope Therapeutics Ltd. from 2016 to 2022, Chairman at SwanBio Therapeutics, Inc. from 2018 to 2023, Chairman at Gyroscope Therapeutics Holdings Plc from 2016 to 2022, Director at Bird Rock Bio Sub, Inc., Director at Convergence Pharmaceuticals Ltd. from 2010 to 2012, Director at Calchan Holdings Ltd., Director at NightstaRx Ltd., Director at Purespring Therapeutics Ltd., Managing Partner at Syncona Ltd., Chief Investment Officer at Syncona Ltd., and Partner at Apposite Capital LLP from 2010 to 2012.
Education includes a doctorate from the University of Cambridge, conferred in 1996.
Cargos activos de Chris Hollowood
| Empresas | Cargo | Inicio |
|---|---|---|
| FREELINE THERAPEUTICS HOLDINGS PLC | Presidente | - |
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Director/Miembro de la Junta | 01/12/2022 |
Forcefield Therapeutics Ltd.
 Forcefield Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics to retain heart function via protection of cardiomyocytes | Presidente | 01/11/2020 |
Syncona Ip Holdco Ltd. | Director/Miembro de la Junta | - |
Freeline Therapeutics Ltd.
 Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which developing gene therapies for bleeding and other debilitating disorders | Fundador | 01/01/2015 |
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners invests in companies located across the globe. The firm focuses on life science businesses and therapeutic areas.. It participates in early stage capital requirements. | Director Ejecutivo | 01/01/2023 |
Antiguos cargos conocidos de Chris Hollowood.
| Empresas | Cargo | Fin |
|---|---|---|
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage gene therapy company that develops treatments for neurological disorders | Presidente | 16/10/2023 |
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Presidente | 17/02/2022 |
Gyroscope Therapeutics Ltd.
 Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Develops gene therapies and medicines for eye diseases | Presidente | 02/02/2022 |
| ░░░░░░░░░ ░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░ ░░░ | ░░░░░░░░ ░░ ░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Formación de Chris Hollowood.
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
75
Relaciones de 1er grado
18
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 18 |
|---|---|
Syncona Ltd.
 Syncona Ltd. Investment Trusts/Mutual FundsMiscellaneous Acts as Closed-End Investment Fund/Investment Trust | Miscellaneous |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical research and development company that provides gene therapy development & clinical research services | Health Technology |
Apposite Capital LLP
 Apposite Capital LLP Investment ManagersFinance Apposite Capital invests in small and medium sized companies located in Europe primarily in the United Kingdom with revenues of up to EUR 100 million. The firm targets companies operating in the fields of digital health, medical products, pharma & life sciences and healthcare services. It provides financing for MBOs, buy-ins and growth capital requirements. It also acquires minority interest. | Finance |
Bird Rock Bio Sub, Inc.
 Bird Rock Bio Sub, Inc. BiotechnologyHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Convergence Pharmaceuticals Ltd.
 Convergence Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops neuropathic pain products | Health Technology |
Calchan Holdings Ltd.
 Calchan Holdings Ltd. Pharmaceuticals: MajorHealth Technology Develops novel oral state-dependent calcium channel (CaV 2.2) modulators for chronic pain | Health Technology |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners invests in companies located across the globe. The firm focuses on life science businesses and therapeutic areas.. It participates in early stage capital requirements. | Finance |
NightstaRx Ltd.
 NightstaRx Ltd. Medical/Nursing ServicesHealth Services development of therapies for retinal dystrophies | Health Services |
Freeline Therapeutics Ltd.
Freeline Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company, which developing gene therapies for bleeding and other debilitating disorders | Health Technology |
Nightstar Therapeutics Ltd.
 Nightstar Therapeutics Ltd. BiotechnologyHealth Technology Operates as a gene therapy company that develops novel treatments for patients suffering from inherited retinal diseases | Health Technology |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Develops gene therapies and medicines for eye diseases | Health Technology |
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage gene therapy company that develops treatments for neurological disorders | Health Technology |
Freeline Therapeutics Holdings Plc
 Freeline Therapeutics Holdings Plc BiotechnologyHealth Technology Develops and manufactures next-generation gene therapies | Health Technology |
Purespring Therapeutics Ltd.
 Purespring Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics for the treatment of kidney diseases | Health Technology |
Gyroscope Therapeutics Holdings Plc
 Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Develops clinical-stage gene therapies to treat diseases of eyes | Health Technology |
Forcefield Therapeutics Ltd.
Forcefield Therapeutics Ltd. BiotechnologyHealth Technology Develops therapeutics to retain heart function via protection of cardiomyocytes | Health Technology |
Syncona Ip Holdco Ltd. |
- Bolsa de valores
- Insiders
- Chris Hollowood
